A new analysis is taking aim at the age-old argument in pharma that drug prices are strongly linked to the cost of innovation. According to the report, which was recently published in a medical ...

A Tufts analysis found that an AI clinical monitoring agent could deliver up to $21 million in value for a late-stage program ...

Late-stage drugs in pancreatic cancer, multiple myeloma and Alzheimer’s could pair treatment advances with major commercial ...

Can Michael Halstead replicate the controlled growth he pulled off at Intra-Cellular Therapies in mental health’s psychedelic ...

Dealmaking in the autoimmune space is thriving as biotechs chase new targets with the potential to treat more conditions.

CEOs can make or break a company. And new leaders at three of pharma’s largest drugmakers are taking over with little room for error. All three leaders took the ...

What started as two neighbors trading shop talk has grown into Tyra Biosciences, a clinical-stage biotech company with a ...

Moderna notched a hard-fought FDA win earlier this month when the agency approved mFlusiva for adults aged 50 and older, ...

Heidi Overton, a medical doctor and veteran of the America First think tank, currently serves as deputy director of the White ...

Less than a month after taking over as interim CEO of Legend Biotech, Alan Bash is signaling continuity rather than a reset. Bash joined Legend in October 2024 to lead its Carvykti business after two ...